Lots of hot money going into JUNO, KITE and the CAR T therapy. Problem with the fantastic early results are that the CAR T treatments are $500,000 yearly with monthly treatments that could go on for.... Sorry, not a nation in this world can afford that kind of health care.
What is this huge short position all about?
03 March 2015
Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada
Short term bad news for stock? Long term Pradaxa is not the anticoagulant doctors want to go with.
January 29th, 2015
Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo in Advanced Refractory Solid Tumors
Short boys not likely to see a pullback as immune based chemo therapy keeps gaining headlines. BMY getting early approval today creating some panic on the short side? ASCO news should also start putting even more focus on immune based chemo.
May 14, 2014
Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab
*Before selling on this pop everyone should take 30 minutes to review the promise of PD-1 and how it works with immune based cancer therapy.
Price goes higher and algo shorts pile on. You Wall Street guys need to pull the plug and fire the boys that wrote that algo you are using.
Perelman could give a shite about animosities. He wants to pocket every last dollar possible. He is a billionaire.
Just a few of the pluses that come with a settlement:
Settle the case and Siga can use it's $54M already written down in BK court, I'm sure there is a lot more. Settle with a merger and Pharmathene has at least $100M plus of tax loss carry forwards.
It's business. Lets just all hope we have decent management teams when it comes time to rewarding shareholders
Cash is not going to be a problem. Siga wants to use it's best accounting tricks to maximize writeoffs...and then I suspect to hear of a negotiated settlement. Settle out of court and you don't have bad faith with ill intent on your record and you also could get to keep the lottery ticket of having the only smallpox antiviral shown safe in human trials and 100% effective in primate trials when primates were injected with a lethal dose of smallpox.
If one case of smallpox turns up you have a multibillion dollar payday. Remember the found CDC smallpox samples found earlier this year. Russia is much less stable and also has viable smallpox stored. You also likely have at least one more BARDA order in the next 5 years.
Anyone else think Siga has turned the Pharmathene case over to their accounting department at this point? Their legal hand has already done an incredible job to get the settlement as low as it has, $190M.
Seeing Siga's price action recently maybe they are about to ink another sizable deal. Ebola and Measles stories help American public appreciate value of these programs. NIH says one case of smallpox found in the world would be considered catastrophic.
Maybe boys getting into Siga know something? That is how Wall Street works. PIP to be gobbled up soon?
Have you seen video of opening argument by Siga to Delaware Supreme Court? Ran across actual video with audio of Siga's opening presentation. Google under cvn video and you will find it. At about 2 minutes 30 seconds the attorney states that it is "fact" that Siga and Pharmathene both think the value of -246 has tripled by November 2006.
(Siga attorney uses the tripling of value as reason that LATS terms should no longer apply)
I'd be interested in you listening to it and give me your opinion. Another appeal at this point sounds absurd from Siga's viewpoint. I'm fine if you point out negatives in your argument. I don't love or hate a stock, I do enjoy a sensible conservation.
The shorts are so focused on discrediting Teebrane, it's replaced the wild speculation articles. I've seen little valuable input from the negative posters on this board.
The original "non binding" negative posters are the real gut busters.
Hang in there and know that your posting some very valuable insights that are read by many that are here for the long run.
I'm in no rush and have cleared cash to collect on price panics from here. This bottoming out and creep up has my trigger finger itching, especially with the Siga boyz getting some strong action.
Pharmathene is up another $34 grand today.
Interesting observation on less basal needed.
A1C's are going to improve with compliance and fewer post prandial spikes not occurring means less basal insulin needed to maintain targeted A1C.
I'm guessing the compliance issue with mealtime injections is much larger than calculated. Affrezza gonna be so much simpler and why would anyone skip it because you don't have the annoying needle #$%$...
(Siga not required to pay expert witness that was not helpful)
* Siga will be required to help pay for witness testimony that was considered helpful in determining reasonable expectations.
Some (((speculation))) has to be used to determine reasonable expectations. Are we still beating that dead horse?
Decided: May 24, 2013
(Siga not required to pay expert witness unhelpful)
On remand, the Vice Chancellor shall redetermine his damage award in light of this opinion and is free to reevaluate the helpfulness of expert testimony.
Note the Delaware Supreme Court says NOT TOO SPECULATIVE.
Based on ordering for National Stockpile
Not based on passing a phase III trial for FDA approval.
*** A Huge difference
I think you mean too speculative. Speculative is a very broad concept.
PharmAthene also contends that the Vice Chancellor erroneously failed to award PharmAthene its lump-sum expectation damages on the basis that they would be too speculative. We (Delaware Supreme Court) do not reach this claim either, because we reverse the Vice Chancellor’s damages award and remand for him to reconsider it in light of this opinion.
IN THE SUPREME COURT OF THE STATE OF DELAWARE
Decided: May 24, 2013